Zydus Lifesciences announced that the safety and efficacy analysis data from the phase-III clinical trial of its Covid-19 vaccine ZyCoV-D has been examined and published in The Lancet, a reputed and well known medical journal.
The clinical trial of ZyCoV-D was one of the most significant trials for a Covid-19 vaccine in India. It was conducted on more than 28,000 adult volunteers at over 50 sites. The vaccine has shown good stability at a temperature of 25 degrees C for at least three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine and lower any cold chain breakdown challenges.
- Dozee Secures $8 Mn to Boost Global Expansion
- Delhi Govt Allocates Rs 2,144 Crore for Ayushman Bharat in First Budget
- India Considers Tariff Reductions on $23 Billion in US Imports to Protect $66 Billion in Exports
- Trump Announces 25% Additional Tariff on Venezuela Trade
- Best 10 Reasons To Invest In Gold: Benefits of Investing in Gold
According to Zydus, the plug-and-play technology of the vaccine allows it to adapt to the SARS COV-2 virus. The trial was done during the peak of the second wave of the Covid-19 virus. The effectiveness of the vaccine stood at 66.6 per cent against the Delta Variant.
